Trials / Completed
CompletedNCT03040089
Efficacy and Safety of Picosecond, Neodymium-doped Yttrium Aluminum Garnet Laser Therapy Using 1,064 nm and 595 nm
Efficacy and Safety of Picosecond, Neodymium-doped Yttrium Aluminum Garnet Laser Laser Therapy Using 1,064 nm and 595 nm on Patients With Melasma: A Prospective, Multi-center, Split Face, 2% Hydroquinone Cream-controlled Clinical Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- CynosureLutronic · Industry
- Sex
- Female
- Age
- 19 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, multi-center, split-face, controlled clinical trial that aims to investigate the efficacy and safety of picosecond, neodymium-doped yttrium aluminum garnet laser laser therapy on patients with melasma, compared with 2% hydroquinone cream. The trial will be performed by two Korean institutions on 45 subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | PICO+4 | picosecond, neodymium-doped yttrium aluminum garnet laser |
| DRUG | Neoquine Cream 2% | 2% hydroquinone cream |
Timeline
- Start date
- 2016-03-09
- Primary completion
- 2016-07-15
- Completion
- 2016-09-26
- First posted
- 2017-02-02
- Last updated
- 2017-02-02
Source: ClinicalTrials.gov record NCT03040089. Inclusion in this directory is not an endorsement.